ARIAD Pharmaceuticals  

Company News

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2014 Financial Results
ARIAD Pharmaceuticals (January 29, 2015)
ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer
ARIAD Pharmaceuticals (January 22, 2015)
ARIAD Announces Final Decision from European Commission Endorsing Iclusig’s Approved Indications Throughout Europe
ARIAD Pharmaceuticals (January 20, 2015)
ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years
ARIAD Pharmaceuticals (January 13, 2015)
ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
ARIAD Pharmaceuticals (January 06, 2015)
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries
ARIAD Pharmaceuticals (December 30, 2014)
ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries
ARIAD Pharmaceuticals (December 23, 2014)
ARIAD and Otsuka Announced Co-development and Commercialization Agreement for Iclusig® to Treat Leukemias in Japan and Nine Other Asian Countries
Otsuka Holdings (December 23, 2014)
CART hype departs from reality (December 22, 2014)
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference
ARIAD Pharmaceuticals (December 22, 2014)

Displaying 10 out of a possible 806 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile ARIAD Pharmaceuticals (ARIA) is a Massachusetts based biotechnology company focused on development & marketing of anti-cancer drugs that function by regulating the cell signalling pathways.
Listed or Private Company Listed
Company Classification Biotechnology; Genomics
Country USA
Company Website Website
Full Company Profile Information

PARTNERING OPPORTUNITIES (Click on Product Name for Full Details)

Product Available for Partnering Opportunity Comment Available USA Available Europe Available Japan Available RoW Markets Detail
Iclusig Yes Company plans for commercialisation of ponatinib on its own in US & potentially in Europe and a regional partnership for the product in select ex-US markets. No Yes Yes Yes WW ex USA

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
11/12/2014 11 Dec: Credit Suisse downgrades rating to "underperform" from "neutral" and lowers price target to $6 from $8. 1,212 -7.7% -102

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
ARIAD Pharmaceuticals 1 41


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

EP Vantage - last 6 months
CART hype departs from reality (December 22, 2014)
Winners and losers – ASH is the new Asco (December 11, 2014)
Amgen leukaemia drug zooms to US launch (December 04, 2014)
Esmo preview – Immuno-oncology and beyond (September 17, 2014)

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now